卵巢癌相关易感基因的研究进展

doi:10.20047/j.issn1673-7210.2023.23.10

Abstract
Figure/Table
References (39)
Related Citation (15)

Download: PDF (547 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract At present, the treatment of ovarian cancer is mainly limited to surgery and chemotherapy. Due to the lack of early detection means and low drug sensitivity, the recurrence rate and death rate are still high for many years. Therefore, the development of new treatment strategies is critical. With the wide application of gene detection technology in ovarian cancer patients, studies have found that the abnormal changes of myeloid cell oncogenes, telangiectasia ataxia mutant genes, transfer-related genes 1, and lactoserine protease inhibitor genes can play an important role in the occurrence, development and drug resistance of ovarian cancer as cancer promotion or tumor suppressor genes. This article reviews the mechanism of action of the above susceptibility genes in ovarian cancer, and provides some theoretical basis for the application of gene editing and gene expression regulation technology in ovarian cancer in the future.

Key words： Ovarian cancer Cellular myelocytomatosis oncogene Ataxia telangiectasia-mutated gene Metastasis-associate gene 1 Marray serine proteinase inhibitor Diagnosis Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Hui HUANG Shouguo

Cite this article:

WU Hui HUANG Shouguo. Research progress of ovarian cancer related susceptibility genes[J]. 中国医药导报, 2023, 20(23): 52-55.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.23.10 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I23/52

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[2] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[3] ■ilovi■ D，■iurlien■ R，Sabaliauskait■ R，et al. Future Screening Prospects for Ovarian Cancer [J]. Cancers （Basel），2021，13（15）：3840.
[4] Kuroki L，Guntupalli SR. Treatment of epithelial ovarian cancer [J]. BMJ，2020，371：m3773.
[5] Lheureux S，Braunstein M，Oza AM. Epithelial ovarian cancer：Evolution of management in the era of precision medicine [J]. CA Cancer J Clin，2019，69（4）：280-304.
[6] Gaona-Luviano P，Medina-Gaona LA，Maga?觡a-Pérez K. Epidemiology of ovarian cance [J]. Chin Clin Oncol，2020，9（4）： 47.
[7] Madden SK，de Araujo AD，Gerhardt M，et al. Taking the Myc out of cancer：toward therapeutic strategies to directly inhibit c-Myc [J]. Mol Cancer，2021，20（1）：3.
[8] Baluapuri A，Wolf E，Eilers M. Target gene-independent func- tions of MYC oncoproteins [J]. Nat Rev Mol Cell Biol，2020， 21（5）：255-267.
[9] Dhanasekaran R，Deutzmann A，Mahauad-Fernandez WD，et al. The MYC oncogene-the grand orchestrator of cancer growth and immune evasion [J]. Nat Rev Clin Oncol，2022，19（1）：23-36.
[10] Reyes-González JM，Vivas-Mejía PE. c-MYC and Epithelial Ovarian Cancer [J]. Front Oncol，2021，11：601512.
[11] Li H，Qi Z，Niu Y，et al. FBP1 regulates proliferation，metastasis，and chemoresistance by participating in C-MYC/ STAT3 signaling axis in ovarian cancer [J]. Oncogene，2021， 40（40）：5938-5949.
[12] 王庆海.上皮性卵巢癌中ZEB2和C-myc蛋白的表达及临床意义[D].广州：南方医科大学，2016.
[13] Liu X，Zuo X，Sun X，et al. Hexokinase 2 Promotes Cell Proliferation and Tumor Formation through the Wnt/β-catenin Pathway-mediated Cyclin D1/c-myc Upregulation in Epithelial Ovarian Cancer [J]. J Cancer，2022，13（8）：2559- 2569.
[14] Dai L，Wang W，Liu Y，et al. Inhibition of sphingosine kinase 2 down-regulates ERK/c-Myc pathway and reduces cell proliferation in human epithelial ovarian cancer [J]. Ann Transl Med，2021，9（8）：645.
[15] Sun J，Cai X，Yung MM，et al. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer [J]. Oncogene，2019，38（4）：564-580.
[16] Bagratuni T，Mavrianou N，Gavalas NG，et al. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer [J]. Eur J Cancer，2020，126：125-135.
[17] Warren C，Pavletich NP. Structure of the human ATM kinase and mechanism of Nbs1 binding [J]. Elife，2022，11：e74218.
[18] Phan LM，Rezaeian AH. ATM：Main Features，Signaling Pathways，and Its Diverse Roles in DNA Damage Response，Tumor Suppression，and Cancer Development [J]. Genes（Basel），2021，12（6）：845.
[19] Lee JH，Paull TT. Cellular functions of the protein kinase ATM and their relevance to human disease [J]. Nat Rev Mol Cell Biol，2021，22（12）：796-814.
[20] Hall MJ，Bernhisel R，Hughes E，et al. Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated （ATM） Gene are Associated with High and Moderate Risks for Multiple Cancers [J]. Cancer Prev Res （Phila），2021，14（4）：433-440.
[21] 鲁强，张志磊，邹存华，等.卵巢上皮性肿瘤组织ATM基因表达缺失及其临床意义的探讨[J].中华肿瘤防治杂志，2011，18（10）：799-801，804.
[22] 樊卫，祁金友，韩笑.CA125、HE4和ATM蛋白联合检测对卵巢癌的诊断价值[J]现代医药卫生，2015，31（24）：3717-3718，3721.
[23] Liu HY，Zhang YY，Zhu BL，et al. MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM [J]. J Ovarian Res，2019，12（1）：60.
[24] Coelho R，Tozzi A，Disler M，et al. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer [J]. Cell Death Dis，2022，13（10）：909.
[25] Nicholson HA，Sawers L，Clarke RG，et al. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer [J]. Br J Cancer，2022，127（7）：1340-1351.
[26] Toh Y，Pencil SD，Nicolson GL. A novel candidate metastasis-associated gene，mta1，differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA clo- ning，expression，and protein analyses [J]. J Biol Chem，1994， 269（37）：22958-22963.
[27] 宋振，金平.肿瘤转移相关基因1与妇科恶性肿瘤关系的研究进展[J].中国临床新医学，2022，15（7）：662-665.
[28] 杨淑慧，周琳，李银珍，等.MTA1通过HIF-1α上调MTDH基因表达促进肺癌细胞增殖与活力[J].重庆医学，2021，50（9）：1451-1455，1460.
[29] 张莉，邓姜云，韩林育.卵巢癌患者组织中SCCA及MTA1表达水平及其与临床特征的关系[J].海南医学，2021， 32（23）：3007-3010.
[30] Guo N，Zhang J. Interleukin-17 promotes the development of ovarian cancer through upregulation of MTA1 expression [J]. Am J Cancer Res，2022，12（12）：5646-5656.
[31] He X，Zhou C，Zheng L，et al. Overexpression of MTA1 promotes invasiveness and metastasis of ovarian cancer cells [J]. Ir J Med Sci，2014，183（3）：433-438.
[32] 刘会.乳源六肽（LfcinB 4-9）促进DDP对人卵巢癌细胞克隆和转移的抑制及其分子机制[D].合肥：安徽医科大学，2021.
[33] Gurzu S，Jung I. Subcellular Expression of Maspin in Colorectal Cancer：Friend or Foe [J]. Cancers （Basel），2021，13 （3）：366.
[34] 莫秋荣，赵苑池，杜杨君，等.子宫内膜增生、子宫内膜样腺癌组织中Twist与maspin的表达及相关性分析[J]. 现代肿瘤医学，2021，29（18）：3266-3270.
[35] 刘碧霞.SERPINB5促进结直肠癌侵袭转移的机制研究[D].南昌：南昌大学，2022.
[36] Wang N，Chang LL. Maspin suppresses cell invasion and migration in gastric cancer through inhibiting EMT and angiogenesis via ITGB1/FAK pathway [J]. Hum Cell，2020，33（3）：663-675.
[37] Sopel M，Surowiak P，Berdowska I. Nuclear maspin expression as a good prognostic factor in human epithelial ovarian carcinoma [J]. Folia Morphol （Warsz），2010，69（4）：204- 212.
[38] 王英，闪海霞，孙勃.上皮性卵巢癌组织NFAT3、Maspin表达及临床意义[J].实验与检验医学，2020，38（4）：783- 786.
[39] 桑娜.Maspin、Bcl-2和Bax在卵巢上皮性肿瘤中的表达及意义[J].中国社区医师，2020，36（16）：124-125.